Pemphigus Vulgaris Treatment Guidelines

Initial Treatment Strategy

The American College of Dermatology recommends starting prednisolone at 1 mg/kg/day for most patients, with doses ranging from 40-60 mg/day for mild disease and 60-100 mg/day for severe disease 1, 2
If no response is seen within 5-7 days, the dose should be increased in 50-100% increments until disease control is achieved, defined as no new lesions and healing of existing ones 1, 2
For doses exceeding 100 mg/day or rapidly progressive disease, switching to pulsed intravenous methylprednisolone 250-1000 mg is recommended 1, 2
Prednisolone is preferred over betamethasone or dexamethasone in pregnant patients as it is 90% inactivated by the placenta 1
A steroid-sparing agent, such as azathioprine 2-3 mg/kg/day or mycophenolate mofetil 2-3 g/day, should be added immediately at treatment initiation to minimize corticosteroid exposure and associated mortality 1, 2

Azathioprine 2-3 mg/kg/day requires normal TPMT testing first 1
Mycophenolate mofetil 2-3 g/day in divided doses, or mycophenolic acid 720-1080 mg twice daily if GI intolerance occurs, can be used as an alternative 1
Expect a 6-8 week latent period before these agents demonstrate clinical effect 1

Implement bone protection measures immediately upon starting corticosteroids, as recommended by the British Journal of Dermatology 1, 2

Once remission is achieved, reduce prednisolone by 5-10 mg weekly initially, and taper more slowly below 20 mg daily 1, 2
Aim to reach ≤10 mg daily or less, and continue adjuvant immunosuppression during taper 1

Treatment failure is defined as continued disease activity despite 3 weeks of prednisolone 1.5 mg/kg/day, or failure to respond after 12 weeks of azathioprine, mycophenolate mofetil, cyclophosphamide, or methotrexate 1
Switch to an alternate steroid-sparing agent if first-line adjuvant fails 1

Rituximab is the preferred third-line agent, demonstrating superior efficacy with 89% complete remission rates at 2 years when combined with short-term corticosteroids, as recommended by the American College of Dermatology 3
Clinical response typically begins within 6 weeks 3
Continue adjuvant immunosuppressants but reduce doses to decrease infection risk 4
For rituximab-resistant cases, consider immunoadsorption combined with rituximab, which can reduce desmoglein antibodies by up to 95% 3

Cyclophosphamide protocols, such as the Dexamethasone-Cyclophosphamide Pulse (DCP) Therapy, can be used as an alternative, with a reported 86% remission off therapy for ≥2 years and 2% mortality 5, 4
Intravenous immunoglobulin, immunoadsorption, methotrexate, and plasmapheresis are other options, although plasmapheresis has shown no benefit over steroids alone in one RCT 1, 2

Pneumocystis jirovecii prophylaxis with trimethoprim/sulfamethoxazole 800/160 mg on alternate days or 400/80 mg daily is recommended for all patients on cyclophosphamide, as advised by the American College of Dermatology 6
Infection and sepsis are major causes of mortality, and high vigilance should be maintained 1
Do not withdraw treatment prematurely, as 47% of successfully treated patients relapse when treatment is stopped after only 1 year 1
Expect delayed response from adjuvants, and maintain adequate corticosteroid coverage during this period 1
Monitor for cyclophosphamide toxicity, including amenorrhea, azoospermia, and pituitary-adrenal suppression 5, 6
Relapse after rituximab occurs in up to 65% of patients, typically 13-17 months post-treatment, and close monitoring is necessary 3

The British Association of Dermatologists guidelines recommend maintaining the current prednisone dose when switching from cyclophosphamide to mycophenolate mofetil, typically aiming for ≤10 mg daily, as the patient likely still requires adequate corticosteroid coverage 7, 8
If disease is not controlled, a temporary increase in prednisone to 1 mg/kg/day may be necessary while mycophenolate mofetil takes effect, with a strength of evidence based on clinical experience 7, 8

The standard dose of mycophenolate mofetil is 2-3 g per day in divided doses, with a strength of evidence based on clinical trials 7, 9, 8
Higher doses of mycophenolate mofetil (2.5-3 g per day) may be required to induce remission in some patients, with a moderate strength of evidence based on observational studies 9, 10

A randomized controlled trial comparing pulsed cyclophosphamide with mycophenolate mofetil in patients with pemphigus vulgaris showed no significant differences in efficacy or adverse events, with a high strength of evidence based on the trial design 11

The British Association of Dermatologists guidelines emphasize the importance of monitoring for the 6-8 week lag period before mycophenolate mofetil becomes clinically effective, to avoid premature reduction of corticosteroids, with a moderate strength of evidence based on clinical experience 9
Most studies examining corticosteroid-related harms in systemic lupus erythematosus identified thresholds of mean 5-7.5 mg/day prednisone associated with various side effects, reinforcing the goal of tapering to ≤10 mg daily, with a high strength of evidence based on systematic reviews 12, 13